Innate Pharma (IPHA) Stock Chart & Stock Price History $1.78 +0.02 (+0.85%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Innate Pharma Stock Price Performance The Innate Pharma (IPHA) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 16.98%, with a year-to-date return of -2.99%. In the past month, the stock has decreased 4.03%, reflecting recent market activity. As of the latest close, Innate Pharma traded at $1.77 with a market cap of $163.16 million and volume of 3,871 shares. Five years ago, the stock traded at $6.06, representing a 70.54% decrease over that period. At the time, it had a market cap of $467.66 million and a volume of 4,000 shares. Receive IPHA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+2.40%1 Month Performance-4.03%3 Month Performance-7.99%Year-To-Date Performance-2.99%1 Year Performance-16.98%5 Year Performance-70.54% IPHA Stock Chart for Wednesday, July, 16, 2025 IPHA Chart by TradingView Innate Pharma Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/15/2025$1.70$1.77+4.12%$1.77$1.713,871 shs$163.16 million07/14/2025$1.74$1.70-2.48%$1.75$1.705,697 shs$156.71 million07/11/2025$1.81$1.74-3.69%$1.81$1.704,886 shs$160.69 million07/10/2025$1.72$1.81+5.23%$1.81$1.7112,591 shs$166.84 million07/09/2025$1.75$1.72-1.71%$1.75$1.727,208 shs$158.55 million07/08/2025$1.79$1.75-2.23%$1.80$1.755,241 shs$161.32 million07/07/2025$1.82$1.79-1.70%$1.81$1.785,539 shs$165.00 million07/04/2025$1.82$1.82$1.81$1.81204 shs$167.86 million07/03/2025$1.82$1.82+0.05%$1.81$1.81204 shs$167.85 million07/02/2025$1.85$1.82-1.36%$1.90$1.825,448 shs$167.77 million Get the Latest News and Ratings for IPHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 07/01/2025$1.82$1.85+1.65%$1.85$1.775,454 shs$170.07 million06/30/2025$1.85$1.82-1.89%$1.85$1.7114,261 shs$167.31 million06/27/2025$1.91$1.85-3.14%$1.92$1.823,484 shs$170.53 million06/26/2025$1.82$1.91+5.23%$1.91$1.754,859 shs$176.06 million06/25/2025$1.78$1.82+2.02%$1.78$1.7217,867 shs$167.31 million06/24/2025$1.80$1.78-1.17%$1.80$1.7623,418 shs$163.98 million06/23/2025$1.80$1.80$1.88$1.7120,145 shs$165.92 million06/20/2025$1.90$1.80-5.26%$1.85$1.809,046 shs$165.92 million06/19/2025$1.90$1.90$1.90$1.834,654 shs$175.13 million06/18/2025$1.87$1.90+1.60%$1.90$1.834,654 shs$175.14 million06/17/2025$1.86$1.87+0.54%$1.92$1.826,508 shs$172.37 million06/16/2025$1.90$1.86-1.85%$1.94$1.8452,584 shs$171.45 million Related Companies AUTL Stock Price Chart STOK Stock Price Chart URGN Stock Price Chart PHAT Stock Price Chart RLAY Stock Price Chart ABUS Stock Price Chart TNGX Stock Price Chart CDXC Stock Price Chart DNTH Stock Price Chart MENS Stock Price Chart Receive IPHA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:IPHA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
